Scyphostatin is a specific inhibitor for mammalianneutral magnesium-dependent sphingomyelinase with a fifty percent inhibition concentration (IC50) value of 1.0 fiM. When used to inhibit lysosomal acid sphingomyelinase, an approximately 50-fold greater concentration is required. In humanperipheral monocytes, the compoundinhibits bacterial lipopolysaccharide (LPS)-induced prostaglandin E2 production and LPS-induced interleukin-ljS production with IC50 values of 0.8 /iM and 0.1 /iM, respectively. In rat, p.o. administration of the compoundhas also been shown to inhibit carrageenin-induced paw edema. Thus, it is hoped that utility ofscyphostatin as a pharmacological tool will contribute to our understanding of the role of ceramide in the cellular inflammation process. As reported in a preceding paper, scyphostatin, a new inhibitor ofN-SMase, has been isolated from the culture broth of Trichopeziza mollissima. This paper describes the biological activities of scyphostatin with a primary focus on the inflammation processes stimulated by LPS.
Materials and Methods

Materials
Unless otherwise specified, all reagents were obtained from Sigma. All the cell lines were purchased from the atmosphere of 5% CO2 and 95% air. The medium used in this study was either RPMI1640 (GibcoBRL) or Dulbecco's modified Eagle's medium (GibcoBRL) supplemented with 10% heat-inactivated fetal calf serum, 100units/ml penicillin G, and lOOjUg/ml streptomycin sulfate. For enzymepreparations, cells were allowed to grow to 60~80%confluence and then washed, collected, and treated as indicated.
SMase Assay and Other EnzymeAssays Preparation of the N-SMasefraction from rat brains was performed by the methods described in the previous converting enzyme by the method of Thornberry et al.17) . The mixed micelle assay system described in the previous paper was used for the measurement of N-SMase activity, wjth a slight modification in 0.1 mM [TV-methyl-14C] sphingomyelin. A-SMase activity was also measured under the same condition used for the N-SMase assay, but in this case the pH was 5.6, magnesium was omitted, and the enzyme source replaced with rat liver lysosomal fraction. The other enzyme assays were carried out as follows: PC-PLCby the method of Wuet al.14); PA-phosphohydrolase by the method of Panagia et al.15) ; Cathepsin L by the method ofBarrett et a/.18); and IL-1/? converting enzyme by the method of Howard et al.19 ).
Productions of the Inflammatory Mediators in Human Monocytes
Adherent monocytes were isolated from human peripheral blood. After incubating the monocytes (1.0 x 105 cells/ml) stimulatedby 10fig/ml LPS for4 or 24 hours, the PGE2, IL-ljff, TNFa, IL-6, and IL-8 levels in the conditioned medium were measured by ELISA kits. Scyphostatin was added to this system together with the LPS-addition. Cell toxicities of scyphostatin for the monocytes were tested by AlmarBluereagent. Carrageenin-induced Paw Edema Study Male Wistar-Imamichi rats used in this study were purchased from Imamichi Institute of Animal Reproduction, Ibaraki, Japan. After an administration of scyphostatin or vehicle to the rat (6 weeks old, weight 120~l40g), an inflammation-inducing solution of 1% carrageenin (Viscarin402) in 0.9% NaCl was subcutaneously injected into the bottom of the paw. After 3 hours, the volume of paw edema was measured by plethysmometer (Ugo Basile) by soaking the paw in a bucket of water, and the results were given as an edemaintensity. Acute toxicity of scyphostatin in vivo was tested using mice (ddY, male, 5 weeks old) purchased from Japan SLC Co., Ltd. through the p.o. administration of 300 mg/kg scyphostatin in corn oil. The animals were observed for 7 days and dissected.
Results and Discussion
Specificity of Scyphostatin in Enzyme Inhibition
Scyphostatin was discovered in the fermentation broth of Trichopeziza mollissirna during the course of a screening for N-SMase inhibitors. In addition to inhibiting N-SMase activity derived from rat brain microsome with a concentration required for 50%inhibition (IC50) of 1.0/iM (Table 1) , scyphostatin also inhibits the N-SMaseactivities using membranefractions from the following mammalian cell-lines with IC5Os of the same order: human myeloid leukemia U937, human leukemia production in humanmonocytes.
Molt-4, murine fibrosarcoma L929, and human T cell leukemia Jurkat (data not shown). Thus, to our knowledge, scyphostatin is the most potent inhibitor for N-SMases in the cell-free system.
Our next aim was to assess the specificity of scyphostatin on enzyme inhibition.
For this assessment, weexamined the effects of the compound on the other SMases, phosphatidylcholine (PC)-phospholipase C, and phosphatidic acid (PA)-phosphohydrolase. Furthermore, since the compound possesses an electrophile epoxy-enone moiety, we also examined the effects on SH-bearing enzymes. As shown in Table 1 , scyphostatin inhibits A-SMase activity at an IC50 of 49.3 //m, a value only about one-fiftieth ofIC50 for inhibition ofN-SMase activity.
On the other hand, scyphostatin showed virtually no inhibitory activity towards bacterial SMases, PC-phospholipase C, PA-phosphohydrolase, Cathepsin L, and IL-lyS converting enzyme (Table 1) . These results indicate that scyphostatin is a specific inhibitor for N-SMase. As one interpretation, we postulate that the structural similarity between scyphostatin and ceramide is the rationale for the inhibition-specificity.
Effcets of Scyphostatin on Inflammatory Mediator Production in HumanMonocytes
In order to estimate the activity of scyphostatin on the representative study on LPS-induced PGE2production in human monocytes. As shown in Fig. 1 , when scyphostain was added to the system, LPS-induced PGE2 production after 24 hours was dose-dependently inhibited at an IC50 value of0.8^m. Next, we tested the effects of scyphostatin on inflammatory cytokine productions in the same system. Since both IL-6 and IL-8 productions were secondarily affected by IL-1/? and TNFa, we measured these four cytokine productions after 4 hours of LPSstimulation. In the experiments shown in Table 2 , scyphostatin inhibited IL-1/? production more potently than it did PGE2 and other cytokines. Thus, scyphostatin dose-dependently inhibited the LPS-induced IL-1/? lasae assays. production with a 50% inhibition at 0.1jum, a concentration with no toxicity to the cells (Fig. 2) . Although we are currently unable to offer any speculation about the inhibition mechanism, these results certainly imply that scyphostatin can be classed as a potent inhibitor for IL-I B production.
Effect of Scyphostatin on In Vivo
Acute Inflammation
To evaluate the pharmacological effect of scyphostatin on acute inflammation in vivo, we performed a carrageenin-induced paw edema study. As shown in Table 3 , carrageenin-induced paw edema was dosedependently inhibited by an oral administration of scyphostatin. Since the generation of the paw edemais largely caused by PGE2, the inhibition with scyphostatin appeared to be reflected in the PGE2 production inhibition shown in Fig. 1 . In our investigation of the acute toxicity of scyphostatin in vivo, no abnormality in mice was observed within at least 7 days following an oral administration with an excess concentration of 300 mg/kg scyphostatin (data not shown). Although the mechanism is not sufficiently clarified, our results suggest that an endogenousceramide released through the N-SMase cycle transduces signaling in LPS-and several inflammatory cytokines-activated immunecells. The present study also indicates that scyphostatin may provide us with a useful tool for exploring the molecular mechanism of cellular inflammation processes. 
